TuisDRREDDY • NSE
add
Dr Reddy's Laboratories Ltd
Vorige sluiting
₹1 195,35
Dagwisseling
₹1 193,60 - ₹1 223,20
Jaarwisseling
₹1 074,00 - ₹1 421,49
Markkapitalisasie
1,01 bn INR
Gemiddelde volume
1,48 m
P/V-verhouding
18,96
Dividend-opbrengs
0,66%
Primêre beurs
NSE
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(INR) | Sep. 2024info | J/J-verandering |
---|---|---|
Inkomste | 80,16 mjd | 16,51% |
Bedryfskoste | 29,72 mjd | 24,54% |
Netto inkomste | 12,55 mjd | -15,18% |
Netto winsgrens | 15,66 | -27,20% |
Wins per aandeel | 15,83 | -11,13% |
EBITDA | 22,02 mjd | 8,53% |
Effektiewe belastingkoers | 30,01% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(INR) | Sep. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 63,07 mjd | -7,15% |
Totale bates | 465,96 mjd | 34,27% |
Totale aanspreeklikheid | 156,67 mjd | 66,79% |
Totale ekwiteit | 309,28 mjd | — |
Uitstaande aandele | 833,05 m | — |
Prys om te bespreek | 3,26 | — |
Opbrengs op bates | 10,24% | — |
Opbrengs op kapitaal | 13,21% | — |
Kontantvloei
Netto kontantverandering
(INR) | Sep. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | 12,55 mjd | -15,18% |
Kontant van bedrywe | 9,32 mjd | -48,03% |
Kontant van beleggings | -19,07 mjd | -322,21% |
Kontant van finansiering | 16,15 mjd | 329,53% |
Netto kontantverandering | 6,37 mjd | 1,03% |
Beskikbare kontantvloei | 3,92 mjd | -72,47% |
Meer oor
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
HUB
Gestig
1984
Hoofkwartier
Webwerf
Werknemers
27 048